Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Breast 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × andecaliximab × Clear all
NCT01803282 2020-06-02

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Completed
236 enrolled 21 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02545504 2020-05-26

GAMMA-1

Gilead Sciences

Phase 3 Completed
432 enrolled 19 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡